Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
US specificity was lower in grade III (P < .001), estrogen receptor (ER)-negative (P < .001), progesterone receptor (PR)-negative (P = .004), HER2-positive (P = .015), triple-negative (P = .001), and larger breast tumors (P < .001).
|
31562691 |
2020 |
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Of the 141 breast tumors, 45 samples (32%) had high HRD scores and were associated with high histological grade (P = 0.001), negative progesterone receptor (P = 0.018), high Ki67 index (P = 0.032), and BRCA1 promoter methylation (P = 3.6e-07).
|
30607631 |
2019 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Collectively, these findings support the role of PR-B in breast epithelial cell integrity and reinforce the importance in targeting PR-B as a potential strategy to restrict breast tumor cell invasion and metastasis.
|
31426542 |
2019 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We found that the expression of SNHG6 was significantly upregulated in primary high-grade and progesterone receptor (PR)-positive breast tumours.
|
30826970 |
2019 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Immunohistochemical testing for estrogen receptor (ER), progesterone receptor (PR), human epidermal receptor factor-2 (HER-2), and Ki-67 proliferation index is performed daily to categorize breast tumors into different molecular subtypes.
|
30695671 |
2019 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Comprehensive biomarker analysis of estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67 labeling index was performed on each tissue block of 100 entirely submitted breast tumors in 99 patients.
|
30327501 |
2019 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Progesterone receptor (PR) isoform α is a crucial regulator of breast hormone responsiveness and its hypermethylation plays an important role in the initiation and development of breast tumors.
|
30816620 |
2019 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Moreover, GLS levels were significantly higher in breast tumors from African-American women compared with Caucasian women regardless of ER or PR status.
|
31428575 |
2019 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Discordances between the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), expression between primary breast tumors and their subsequent brain metastases (BM) were investigated in breast cancer patients.
|
28975433 |
2018 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We investigated whether ER and PR-B interactions were present in breast tumours and associated with clinical parameters including response to aromatase inhibitors.
|
30410061 |
2018 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The 26 successfully retrieved archival NF1 breast tumours were more often associated with unfavourable prognostic factors, such as oestrogen and progesterone receptor negativity and HER2 amplification.
|
27931045 |
2017 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
By utilizing a big dataset (TCGA) with sufficient statistical power, we found that high expression of miRNA-18a, miRNA-205, and miRNA-744 in the breast tumor samples were all associated with better overall survival in ER/PR-positive, lymph node-negative disease supporting their role as a tumor suppressor in breast cancer.
|
28766230 |
2017 |
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
However, when combined with MSI/LOH in AR, ERβ and CYP19 genes, we were able to detect significant associations with the GSTP1 wild-type genotype in PR (progesterone receptor) negative breast cancers or the CYP17 wild-type genotype in ER (estrogen receptor) and PR-negative breast tumors.
|
28692125 |
2017 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Breast tumour microarrays from the Nurses' Health Study were stained for ER (n=592) and PR (n=187).
|
27729430 |
2017 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We aimed to investigate estrogen receptor (ER), progesterone receptor (PR) and HER2 concordance in ipsilateral concurrent biopsies with invasive breast tumors.
|
28457730 |
2017 |
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Phospho-Ser294 PR species were abundant in a majority (54%) of luminal breast tumors, and PR promoter selectivity was exquisitely sensitive to posttranslational modifications.
|
28412963 |
2017 |
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Subgroup analyses by menopausal status, hormone receptor status of breast tumors (estrogen receptor [ER], progesterone receptor [PR] and human epidermal growth factor receptor 2 [HER2]), alcohol intake and MTHFR polymorphisms (677C > T and 1298A > C) were also performed.
|
27905104 |
2017 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Although the role of native progesterone in the development of breast cancer remains controversial, PR clearly alters the transcriptome in breast tumors.
|
28684637 |
2017 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Herein, we evaluated the anti-tumor activity of a commercially available PR modulator, ulipristal acetate (UPA), and a new selective and passive PR antagonist "APR19" in a novel preclinical approach based on patient-derived breast tumor (HBCx-34) xenografted in nude mice.
|
26941094 |
2016 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
An interesting association was found between ER/PR (Oestrogen/Progesterone receptor) and HER2/Neu (Human epidermal growth factor receptor-2) positivity with HPV occurrence in breast tumours.
|
27613186 |
2016 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors.
|
27542969 |
2016 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our aim was to document the subtypes defined by immunohistochemistry (IHC) expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2): namely ER + PR+ HER2+; ER + PR + HER2-; ER-PR-HER2+; and ER-PR-HER2- in metastatic breast carcinoma in pleural fluid and compare them with their expression in the primary breast tumor.
|
27666130 |
2016 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In the univariate analysis, younger age, solitary brain metastasis, and ER or PR positivity in the breast tumors were associated with longer survival.
|
25802405 |
2015 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A recent report shows that PR activation inhibits estrogen-driven breast tumor growth by altering ERα chromatin binding and transcriptional activity.
|
26277479 |
2015 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
One-third of estrogen (ER+) and/or progesterone receptor-positive (PGR+) breast tumors treated with Tamoxifen (TAM) do not respond to initial treatment, and the remaining 70% are at risk to relapse in the future.
|
25971350 |
2015 |